This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Thermo Fisher (TMO) and Eli Lilly & Co (LLY)

Tipranks - Tipranks - Thu May 28, 10:20AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teva Pharmaceutical (TEVA), Thermo Fisher (TMO) and Eli Lilly & Co (LLY) with bullish sentiments.

Memorial Day Sale – Claim 70% Off TipRanks

Teva Pharmaceutical (TEVA)

In a report released today, Dennis Ding from Jefferies maintained a Buy rating on Teva Pharmaceutical, with a price target of $40.00. The company’s shares closed last Wednesday at $34.95.

According to TipRanks.com, Ding is a 4-star analyst with an average return of 11.6% and a 50.0% success rate. Ding covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Rhythm Pharmaceuticals, and Olema Pharmaceuticals. ;'>

Currently, the analyst consensus on Teva Pharmaceutical is a Strong Buy with an average price target of $42.11.

See today’s best-performing stocks on TipRanks >>

Thermo Fisher (TMO)

Jefferies analyst Tycho Peterson maintained a Buy rating on Thermo Fisher today and set a price target of $650.00. The company’s shares closed last Wednesday at $449.09.

According to TipRanks.com, Peterson is a 4-star analyst with an average return of 7.2% and a 53.9% success rate. Peterson covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Tempus AI, Inc. Class A, and Bio-Rad Laboratories. ;'>

Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $613.27, which is a 36.3% upside from current levels. In a report released today, TipRanks – DeepSeek also upgraded the stock to Buy with a $495.00 price target.

Eli Lilly & Co (LLY)

In a report released today, David Risinger from Leerink Partners reiterated a Buy rating on Eli Lilly & Co. The company’s shares closed last Wednesday at $1087.73.

According to TipRanks.com, Risinger is a top 100 analyst with an average return of 29.8% and a 63.6% success rate. Risinger covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, Centessa Pharmaceuticals, and Oruka Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1265.10 average price target, which is a 18.0% upside from current levels. In a report issued on May 13, BMO Capital also maintained a Buy rating on the stock with a $1300.00 price target.

Read More on TEVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).